Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status

Internal Medicine

Volumn 41, Issue 12, 2002, Pages 1147-1152

  Takeda, Norifumi ^a   Ohtaki, Eiji ^a   Misu, Kazuhiko ^a   Asano, Ryuta ^a   Tobaru, Tetsuya ^a   Nagayama, Masatoshi ^a   Kitahara, Koichi ^a   Umemura, Jun ^a   Sumiyoshi, Tetsuya ^a   Hosoda, Saichi ^a  

^a SAKAKIBARA HEART INSTITUTE   (Japan)

Author keywords

Interleukin 6; Myocarditis; Reverse remodeling

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOCARPAMINE; FUROSEMIDE; INOTROPIC AGENT; PIMOBENDAN; TETROFOSMIN TC 99M;

ADULT; ARTICLE; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY;

EID: 12244267663     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.1147     Document Type: Article

References (25)

1. Packer M, Bristow MR, Cohn JN, et al. US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349-1355, 1996.
2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353: 2001-2007, 1999.
3. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353: 9-13, 1999.
4. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory Class IV Heart Failure. J Am Coll Cardiol 31: 1336-1340, 1998.
5. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am J Cardiol 85: 1495-1497, 2000.
6. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure - The effects of pimobendan on chronic heart failure study (EPOCH Study) -. Circ J 66: 149-157, 2002.
7. Packer M, Coats AJ, Fowler MB, at al, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658, 2001.
8. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with New York Heart Association Class IV Heart Failure. J Am Coll Cardiol 33: 924-931, 1999.
9. Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83: 1201-1205, 1999.
10. Capomolla S, Febo O, Gnemmi M, at al. β-blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 139: 596-608, 2000.
11. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349: 375-380, 1997.
12. Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol 33: 1400-1407, 1999.
13. Matsumura T, Tsushima K, Ohtaki E, et al. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J Cardiol 39: 253-257, 2002.
14. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CH. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 101: 122-124, 2000.
15. Ohlstein EH, Arleth AJ, Storer B, Romanic AM. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 30: 167-173, 1998.
16. Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkfoff D. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 91: 2717-2720, 1995.
17. Burkhoff D, Holmes JW, Madigan J, Barbone A, Oz MC. Left ventricular assist device-induced reverse ventricular remodeling. Prog Cardiovasc Dis 43: 19-26, 2000.
18. Muller J, Wallukat G, Weng YG, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 96: 542-549, 1997.
19. Muller J, Wallukat G, Dandel M, at al. Immunoglobulin absorption in patients with idiopathic dilated cardiomyopathy. Circulation 101: 385-391, 2000.
20. Li LX, Nohara R, Okuda K, et al. Comparative study of 201Tl-scintigraphic image and myocardial pathologic findings in patients with dilated cardiomyopathy. Ann Nucl Med 10: 307-314, 1996.
21. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation 93: 841-842, 1996.
22. Steimle AE, Stevenson LW, Fonarow GC, Hamilton MA, Moriguchi JD. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 23: 553-559, 1994.
23. Naqvi TZ, Goel RK, Forrester JS, Siegel RJ. Myocardial contractile reverse on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 34: 1537-1544, 1999.
24. Mann-Rouillard V, Fishbein MC, Naqvi TZ, DonMichael TA, Siegel RJ. Frequency of echocardiographic improvement in left ventricular cavity size and contractility in idiopathic-dilated cardiomyopathy. Am J Cardiol 83: 131-133, A139-110, 1999.
25. Naqvi TZ, Goel RK, Forrester JS, Davidson RM, Siegel RJ. Usefulness of left ventricular mass in predicting recovery of left ventricular systolic function in patients with symptomatic idiopathic dilated cardiomyopathy. Am J Cardiol 85: 624-629, 2000.